Circulating tumor DNA (ctDNA) testing is a rapidly evolving tool in oncology, used to detect molecular residual disease after cancer treatment. While these liquid biopsies can identify cancer markers before they appear on standard imaging, clinical guidelines currently do not support using ctDNA results as a definitive trigger for escalating or changing cancer therapies, as evidence of improved patient survival remains limited.
How ctDNA Testing Detects Residual Disease
Circulating tumor DNA consists of small fragments of genetic material shed by tumors into a patient’s bloodstream. According to the National Cancer Institute, clinicians use these tests to identify minimal residual disease (MRD)—tiny amounts of cancer left behind after surgery or systemic therapy. Because these tests are highly sensitive, they can theoretically identify a recurrence months before a patient develops physical symptoms or before a tumor reaches a size visible on a CT or PET scan.
The Clinical Dilemma: Prognosis Versus Prediction
While ctDNA is a powerful prognostic tool, it is not yet a predictive one. Prognostic tools tell doctors about the likely course of a disease, while predictive tools indicate whether a specific treatment will change that outcome.
Evidence from the CIRCULATE-Japan GALAXY trial confirms that ctDNA positivity after surgery is strongly associated with worse disease-free survival in colorectal cancer. However, data from the DYNAMIC-III trial showed that escalating treatment based on a positive ctDNA result did not improve recurrence-free survival compared to standard care. In some cases, aggressive intervention based on molecular findings alone may expose patients to toxic side effects without providing a clear survival benefit.
When Can ctDNA Guide Treatment?
In specific, well-studied scenarios, ctDNA results are beginning to inform clinical decisions. The IMvigor011 trial demonstrated that in patients with muscle-invasive bladder cancer, ctDNA monitoring can help select candidates for adjuvant immunotherapy. Patients who tested positive for ctDNA after surgery saw a significant overall survival benefit when treated with atezolizumab. Conversely, the study suggested that patients who remain consistently ctDNA-negative may safely avoid the risks of unnecessary adjuvant therapy.
Limitations and Known Blind Spots
Liquid biopsies are not infallible. False-negative results can occur if a tumor sheds low amounts of DNA or if the cancer evolves mutations that the specific test is not designed to detect. According to research published in Nature regarding the TRACERx study, while ctDNA is a promising marker, detection remains challenging in early-stage non-small cell lung cancer. Furthermore, some patients may experience clinical progression—such as the spread of cancer to the peritoneum—even when serial blood tests remain negative.
Future Directions in Cancer Monitoring
In the coming years, researchers expect ctDNA to refine how oncologists perform active surveillance. Rather than relying on fixed schedules for scans, future protocols may use ctDNA results to trigger imaging or adjust treatment intensity.
Key Considerations for Patients
- Not a Standard of Care: As of 2026, ctDNA testing is not a universal standard of care for all cancer types.
- The “Lead Time” Reality: While ctDNA can provide early detection for some, it does not guarantee a 9-to-12-month head start for every patient.
- Nuanced Conversations: Patients should discuss the implications of testing with their oncologist, specifically focusing on whether an actionable plan exists if a test returns a positive result.
Because the field is still maturing, clinicians emphasize that a positive ctDNA result should be interpreted within the context of the patient’s overall health, tumor biology, and the availability of proven interventions. Until further trials prove that early intervention changes long-term outcomes, the primary value of ctDNA remains in its ability to monitor disease status rather than dictate immediate therapy changes.